Andre Miguel Miguel, PhD

2012-2016 Ph.D. in Psychiatry and Medical Psychology at the Department of Psychiatry of the Federal University of Sao Paulo (UNIFESP). Sao Paulo, Brazil.

2008-2009 Master in Pathological Dependences, Departments of Psychiatry, Pharmacology, Neurobiology and Biotechnology of the University of Pisa. Pisa, Italy.

2001-2007 Graduated in Clinical Psychology, Pontific Catholic University of Sao Paulo (PUC-SP). Sao Paulo, Brazil.

2023- current – Assistant Professor (tenure-track) at the Department of Community and Behavioral Health, Elson S. Floyd College of Medicine of the Washington State University.  

2020-2023 – Assistant Research Professor at the Department of Medical Education and Clinical Science, Elson S. Floyd College of Medicine of the Washington State University.

2019-2020 –  Associate-in-Research at the Department of Medical Education and Clinical Science, Elson S. Floyd College of Medicine of the Washington State University.  

2018-2019 – Postdoctoral Fellow, Department of Psychiatry at Yale School of Medicine.  

2017-2018 – Postdoctoral Fellow, Department of Psychiatry of the Federal University of Sao Paulo, Brazil.

2010-2018 – Private Practice as a Clinical Psychologist with focus in treating adolescents and adults with substance use disorders in Sao Paulo, Brazil.  

2011-2017 – Researcher for the Brazilian National Institute of Science and Technology for Policies in Alcohol and other Drugs (INPAD).  

2016-2017 – Consultant for the WHO United Nations Development Program in Brazil for the development of a Brazilian best practice guideline for prevention, treatment and social integration of people with substance use disorders.

2011-2017 – Counselor and Lead Coordinator of the “Wilderness Rehabilitation Program” for adolescents with substance use disorders.  

2010-2011 – Clinical Psychologist at the Vila Maria public ambulatory service for alcohol and drugs at the north region of Sao Paulo, Brazil.  

2009 – Counselor at the SERT public ambulatory service for substance use disorders at Lucca, Italy (2009).  

2009 – Counselor at the Vila Adelasia inpatient treatment facility for individuals with a substance use disorders and severe mental comorbidities at Lucca, Italy.  

2002-2007 – Therapeutic Companion for people struggling with substance use disorders.  

Overall my research has focussed in developing and evaluating substance use disorder treatment. 

More specificacly, I’ve been conducting research in the intersection of four main areas:

1. Development of novel tecnologies for substance use disorder treatment (e.g., telehealth, app-based interventions, etc.)
2. Integrating pharmacological and behavioral interventions for substance use disorder
3. Development and evaluation of interventions for substance co-use (e.g., alcohol and smoking; methamphetamine and opioid co-use)
4. Development and evaluation of interventions for substance use disorder for underserved populations (i.e., rural population, homeless population, LMIC), 

1.     Miguel AQC, Akana N, Ryan R, Schimdt A, Hovland S, Stark B, Colletto S, Bowen A, Rodin N, Smith CS, McPherson SM, App-Based Contingency Management to Reduce Heavy Drinking Days among Smokers Receiving Varenicline. Feasibility, Acceptability and Efficacy Indicators from a Phase I Analog Trial. Experimental and Clinical Psychopharmacology. In Press.

2.     Palombo P, Akana N, Bowen A, Schimdt A, Ryan R, Hovland S, Stark BC, Rodin N, Chaytor N, McDonell M, Burduli E, Layton M, Roll JM, Smith CL, Miguel AQC, McPherson SM. The Pharmaceutically Enhanced Reinforcement for Reduced Alcohol and Smoking (PERRAS) Study: Protocol for a Randomized Clinical Trial. Contemporary Clinical Trials. In Press.

3.     Smith CL, McPherson SM, Rodin N, Hovland S, Akana N, Miguel AQC, Marsden J, Saxon AJ. Quality of life and treatment effectiveness direct and indirect effects on cocaine abstinence outcomes during cocaine use disorder treatment. Drug and Alcohol Dependence. In Press

4.     Sousa KS, Sampaio AS, Junior NA, Miguel AQC. Capacitação Remota sobre Manejo de Contingências: Estudo Piloto sobre seus Efeitos nos Conhecimentos e Atitudes de Profissionais. Estudos de Psicologia. 2025

5.     León G, Bae J, Coles C, Batts C, Akana N, Smith CL, McPherson SM, Miguel AQC. Exploring Clinical Profile and Treatment Outcome Differences Based on Baseline Smoking and Alcohol Co-Use Status Among Individuals Initiating Medication for Opioid Use Disorder Treatment. The American Journal on Addictions. 2026

6.     Madruga C, Barreto KIS, Canfield M, Seabra D, Silva CJ, Miguel AQC, Rebouças L, Ferreira N, Godoy G, Cordeiro Q, Laranjeira R. Women Who Use Drugs in Open Drug Scenes: A Brief Cross-Sectional Study from Brazil. Journal of Substance Use. 2025

7.     Madruga CS, Barreto KIS, Canfield M, Seabra D, Garbosa FM, Silva CJ, Miguel AQ, Cordeiro Q, Laranjeira RR. Latent Class Profiles and Factors Associated with Willingness to Change in Open Drug Scenes in Three Brazilian Cities. Trends Psychiatry Psychother. Trends in Psychiatry & Psychotherapy. 2025

8.     Coles C, Batts C, Bae J, León G, Schimdt A, McPherson SM, Smith CL, Miguel AQC. Impact of Recent Stimulant Use on Treatment Outcomes Amongst Individuals Initiating Medications for Opioid Use Disorders: Secondary Analysis of a Multisite Randomized Controlled Trial. Drug and Alcohol dependence Report. 2025; 15, 100330.

9.     Kenefick L, Khairy L, Hall L, Kwon K, Limberg N, Kirk-Lewis K, Lewis M, Owen M, McPherson SM, Miguel AQC. Impact of Recent Methamphetamine Use on Treatment Outcomes Amongst Individuals Initiating Medications for Opioid Use Disorders in Rural treatment settings. A One Year Retrospective Cohort Study. Rural and Remote Health. 2025; 25, 9536.

10.  Madruga CS, Barreto KIS, Seabra D, Miguel AQC, da Silva CJ, Godoy Filho GS, Rebouças LN, Ferreira NA, Bosso RA, Miziara CSMG, Canfield M, Larangeira RR. Addressing reproductive health inequities in Brazil’s open drug scenes: the case for improving uptake of etonogestrel subdermal implant. Revista Brasileira de Ginecologia e Obstetrícia. 2025; 47 e-rbgo60.

11.  Rash CJ, McDonnell M, Erath T, Parent S, Rawson R, Wattenberg S. & Signatories:  Alessi SM, Dallery J, DeFulio A, DePhilippis D, Dunn KE, Gaalema DE, Heil SH, Higgins ST, Hirchak KA, Koffarnus MN, Ledgerwood DM, McPherson SM, Miguel AQC, Reback CJ, Roll J, Shoptaw S, Silverman K, Stanger C, Stitzer M, Weinstock J. A call to action: Evidence-based contingency management. The American Journal of Psychiatry. 2025; 00, 1–4.

12.  Madruga CS, Barreto KIS, Seabra D, Miguel AQC, Silva CJ, Apolinário GS, Godoy GS, Rebouças LN, Ferreira NA, Cordeiro Q, Bosso RA, Laranjeira R. Open Drug Scenes Survey in Brazilian cities: main findings from São Paulo, Fortaleza, and Brasília. Revista Brasileira de Epidemiologia. 2025; 28, e250008.

13.  Barreto KIS, Madruga C, Miguel AQC, Smith CL, Apolinário GS, Godoy Filho GS,  Guirado LR, Kurlander PA, McPherson S,Laranjeira R. Intervention diversity predicts social rehabilitation indicators at discharge in therapeutic communities. Journal of Substance Use & Addiction Treatment. 2024; 162, 209374.

14.  McPherson SM, Smith CL, Hall L, Miguel AQC, Bowden T, Keever A, Schmidt A, Olson K, Rodin N, McDonell MG, Roll JM, LeBrun J. Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I Feasibility, Usability and Efficacy Randomized Clinical Trial. Drug and Alcohol Dependence. 2024; 256, 111099

15.  Miguel AQC, Smith C, Perea N, Johnson K, McDonell MG, McPherson S. Automated Reinforcement Management System: Feasibility study findings of an app-based contingency management treatment for alcohol use disorder. Drug and Alcohol Dependence Reports. 2023;6, 100140

16.  Smith CL, Miguel AQC, Keever A, Bowden T, Burduli E, Roll J, McPherson S. Exploring the Mediating Role of Baseline Urinalysis Results on Demographic Characteristics and Stimulant Use Disorder Treatment Outcomes. Journal of Substance Use & Addiction Treatment. 2023;26, 208962.

17.  Smith CL, Keever A, Bowden T, Olson K, Rodin N, McDonell MG, Roll JM, Smoody G, LeBrun J, Miguel AQC, McPherson SM. Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability. JMIR Formative Research, 2023, 7, e40437. doi:10.2196/40437

18.  Miguel AQC, McPherson S, Simões V, Yamauchi R, Madruga C, da Silva C, Laranjeira Crystal S, Roll J, McDonell M, Mari J. Effectiveness of Incorporating Contingency Management into a Public Treatment Program for Crack Cocaine Users in Brazil. A Single-Blind Randomized Controlled Trail. International Journal of Drug Policy. 2022;99, 103464  

19.  Miguel AQC, Simões V, Yamauchi R, Madruga C, da Silva C, Laranjeira R, Mari J, Roll J, McPherson S, Mari J. Acceptability and feasibility of incorporating Contingency Management to a public treatment for crack users who are homeless in Brazil. A pilot study. Experimental and Clinical Psychopharmacology, 2022.

20.  McPherson SM, Parent S, Miguel AQC, McDonell MG, Roll J. Contingency Management Is a Powerful Clinical Tool for Treating Substance Use: Research Evidence and New Practice Guidelines for Use. Psychiatric Times. 2022; 39(9), 9-11

21.  Smith, CL, Rodin NM, Hwang JY, Miguel AQC, Johnson K, McDonell MG, McPherson SM. Automated Reinforcement Management System (ARMS): Focused provider feedback. Addiction Science and Clinical Practice. 2022; 17(20),1-7.

22.  Miguel AQC, Simões V, Yamauchi R, Madruga C, da Silva C, Laranjeira R, Roll J, McPherson S, Mari J. Sociodemographic and clinical profile of treatment-seeking crack users living in “Crackland”, Brazil. Brazilian Journal of Psychiatry. 2022;71(1), 1-6.

23.  Silva KS, Miguel AQC, Sampaio AS. Contingency Management Applied to Alcohol Use Disorder: Systematic Review. Psicologia: Teoria e Pesquisa, 2022;38.1-10.

24.  Smith C, Cooper BR, Miguel AQC, Hill L, Roll J, McPherson, S. Youth risk profiles and their prediction of distal cannabis and tobacco co-use in the Population Assessment of Tobacco Health (PATH). Substance Abuse. 2022;43(1),733-41.

25.  Silva KS, Sampaio AS, Miguel AQC. Manejo de Contingência Aplicado ao Transtorno por Uso de Álcool: Revisão Sistemática. Psicologia: Teoria e Pesquisa, 2022;38: e38215.

26.  Madruga CS, Miguel AQC, Massaro L, Caetano R, Laranjeira RR. Cannabis Consumption onset and addiction: Data from the second Brazilian Drugs and Alcohol Survey (BNADS). Journal of Psychoactive Drugs. 2021,1-6.

27.  Miguel AQC, Smith C, Perea N, Johnson K, McDonell MG, McPherson S. Automated Reinforcement Management System (ARMS): Phase I Methods and Development. JMIR Formative Research.2021;5(7); e25796.

28.  Smith C, Cooper BR, Miguel AQC, Hill L, Roll J, McPherson, S.  Predictors of marijuana and tobacco co-use in youth: Exploring the mediating role of age at first use in the Population Assessment of Tobacco Health (PATH) study. Journal of Cannabis Research.2021;3(1),1-10.

29.  Miguel AQC, Smith CL, Burduli E, Roll J, McPherson, S. Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes. Experimental and Clinical Psychopharmacology, 2021.

30.   Miguel AQC, Smith CL, Burduli E, Roll J, McPherson, S. Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders. Journal of Substance Abuse Treatment. 2021;124;108291.

31.  Gaya CM, Crippa JAS, Hallak JEC, Miguel AQC, Laranjeira RR, Bressan RA, Zuardi AW, Lacerda, ALT. Cannabidiol for the Treatment of Crack-cocaine Craving: An Exploratory Double-blind Study. Brazilian Journal of Psychiatry, 2021.

32.  Miguel AQC, Simões V, Yamauchi R, Laranjeira R, Mari J, Roll J, McPherson S. Contingency Management Banking: A novel procedure designed to reduce costs and increase the efficacy of contingency management for substance use disorders. Revista Brasileira de Psicologia Comportamental e Cognitiva. 2020;22(1);1424.

33.   Smith C, Jenkins G, Burduli E, Tham, P, Miguel AQC, Roll J, McPherson, S. Crossover Associations of Alcohol and Smoking, Craving and Biochemically Verified Alcohol and Nicotine Use in Heavy Drinking Smokers. Behavior Pharmacology. 2020.

34.  Ribeiro A, Trevizo A, Oluwoye O, McPherson S, McDonnel MG, Briese V, Miguel AQC, Fratzinger RS, Laranjeira RR, Alonso AL, Karasin AL, Ribeiro M, Madruga CS. HIV and syphilis infections and associated factors among patients in treatment at a Specialist Alcohol, Tobacco, and Drugs Center in São Paulo’s “Cracolândia”. Trends in Psychiatry and Psychotherapy, 2020;42(1):1-6.

35.  Miguel AQC, Kiluk BD, Corey R, Babuscio TA, Nich C, Mari JJ, Carroll K M. Change in Employment Status and Cocaine Use Treatment Outcomes: A Secondary Analysis Across Six Clinical Trials. Journal of Substance Abuse Treatment. 2019; 106:89-96.

36.  Miguel AQC, Jordan A, Kiluk BD, Nich C, Babusci o TA, Mari JJ, Carroll KM. Sociodemographic and clinical outcome differences among individuals seeking treatment for cocaine use disorders. The intersection of gender and race. Journal of Substance Abuse Treatment. 2019; 106:65-72.

37.  Miguel AQC, Madruga C, Simões V, Yamauchi R, da Silva CJ, McDonnell MG, McPherson S, Roll J, Mari J, Laranjeira R. Contingency management is effective in promoting abstinence and retention-in-treatment among crack cocaine users with a previous history of poor treatment response. A crossover trial. Psicologia: Reflexão e Crítica. 2019.

38.  Miguel AQC, Kiluk BD, Babuscio TA, Nich C, Mari JJ, Carroll KM. Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders. Drug and Alcohol Dependence. 2019;1; 198:126-132.

39.  Roos C, Nich C, Jung Mun C, Babuscio T, Mendonca J, Miguel AQC, Devito E, Yip S, Witkiewitz K, Carroll KM, Kiluk B. Clinical Validation of Reduction in Cocaine Frequency Level as an Endpoint in Clinical Trials for Cocaine Use Disorder. Drug and Alcohol Dependence. 2019;205

40.  Fonseca LM, Mattar GP, Haddad GG, Gonçalves AS, Miguel AQC, Guilhoto LM, Zaman S, Holland AJ, Bottino CMC, Hoexter MQ. Frontal-subcortical behaviors during Alzheimer’s disease in individuals with Down syndrome. Neurobiology of Aging. 2019; 78:186-194.

41.  Abdalla RR, Miguel AQC, Brietzke E, Caetano R, Laranjeira R, Madruga CS. Suicidal behavior among substance users: data from the Second Brazilian National Alcohol and Drug Survey (II BNADS). Brazilian Journal of Psychiatry. 2019. PMID: 30785535

42.   Miguel AQC, Madruga C, Cogo-Moreira H, Yamauchi R, Simoes V, da Silva CJ, McDonnell MG, McPherson S, Roll J, Mari J, Laranjeira R. Crack cocaine users views regarding treatment with contingency management treatment in Brazil. Substance Abuse Treatment, Prevention, and Policy. 2018;13(1):7.

43.   Madruga C, Paim TL, Palhares HN, Miguel AQC, Massaro LTS, Caetano R, Laranjeira R. Prevalence and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary life. Brazilian Journal of Psychiatry. 2018; 7: 8-13.

44.  Miguel AQC, Madruga C, Cogo-Moreira H, Yamauchi R, Simoes V, da Silva CJ, McDonnell MG, McPherson S, Roll J, Mari J, Laranjeira R. 2018. Sociodemographic characteristics, pattern of crack use, concomitant substance use disorders, and psychiatric symptomatology in treatment-seeking crack-dependent Individuals in Brazil. Journal of Psychoactive Drugs. 2018;50(4):367-372.

45.  Abdalla R, Massaro L, Miguel AQC, Laranjeira R, Caetano R, Madruga C. Association between drug use and urban violence: Data from the II Brazilian National Alcohol and Drugs Survey (BNADS). Addictive Behaviors Reports, 2018;7:8-13.

46.  Miguel AQC, Madruga C, Cogo-Moreira H, Yamauchi R, Simoes V, Ribeiro A, da Silva CJ, Fruci A, McDonnell MG, McPherson S, Roll J, Laranjeira R. Contingency management targeting abstinence is effective in reducing depressive and anxiety symptoms among crack cocaine-dependent individuals. Experimental and Clinical Psychopharmacology. 2017;25(6):466–472.

47.  Miguel AQC, Madruga CS, Cogo-Moreira H, Yamauchi R, Simões V, da Silva CJ, McPherson S, Roll J, Laranjeira RR. Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized controlled trial. Psychology of Addictive Behaviors, 2016;30(5), 536.

48. Miguel AQC, Yamauchi R, Simões V, da Silva C J, Laranjeira RR. From Theory to treatment: Understanding Addiction from an operant behavioral perspective. Journal of Modern Education Review, 2015;5, 778-787.

49. Gaya CM, Madruga C, Miguel AQC, Mitsuhiro S, Pinsky I, Caetano R, Laranjeira R. Fatores Associados A Não Adesão Às Políticas Públicas de Uso e Venda do Álcool no Brasil: I Levantamento Nacional de Álcool e Drogas. Revista Debates em Psiquiatria. 2014;4, 6-14.

50. Miguel AQC, Yamauchi R, Simões V, Laranjeira RR. Do uso esporádico ao padrão de dependência, da teoria ao  tratamento: Uma perspectiva operante do comportamento de autoadministrar substâncias. Boletim Paradigma, 2014;9, 17-24.